Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY28.06 CNY
Change Today -0.26 / -0.92%
Volume 4.6M
As of 3:00 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

walvax biotechnology co-a (300142) Snapshot

Open
CNY28.32
Previous Close
CNY28.32
Day High
CNY28.55
Day Low
CNY27.52
52 Week High
04/24/15 - CNY32.00
52 Week Low
07/24/14 - CNY15.16
Market Cap
13.1B
Average Volume 10 Days
9.7M
EPS TTM
CNY0.31
Shares Outstanding
468.0M
EX-Date
04/23/15
P/E TM
90.9x
Dividend
CNY0.03
Dividend Yield
0.09%
Current Stock Chart for WALVAX BIOTECHNOLOGY CO-A (300142)

Related News

No related news articles were found.

walvax biotechnology co-a (300142) Related Businessweek News

No Related Businessweek News Found

walvax biotechnology co-a (300142) Details

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, is engaged in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It provides bio-medicines, such as vaccines, blood products, and others. The company offers Group A and C meningococcal polysaccharide vaccine for children and adults over the age of 2 years to prevent disease caused by the bacteria named neisseria meningitidis groups A and group C; and haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis, etc. It also provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine; Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. The company was founded in 2001 and is headquartered in Kunming, the People’s Republic of China.

Founded in 2001

walvax biotechnology co-a (300142) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

walvax biotechnology co-a (300142) Key Developments

Walvax Biotechnology Co.,Ltd Approves Amendments to the Company's Articles of Association

Walvax Biotechnology Co.,Ltd approved amendments to the company's articles of association, at the AGM held on 14 April 2015.

Walvax Group Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 11:00 AM

Walvax Group Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 11:00 AM. Venue: Kerry Hotel, Pudong, Shanghai, China. Speakers: Joe Zhou, VP.

Walvax Biotechnology Teams Up with Hangzhou Tigermed Consulting

Walvax Biotechnology Co.,Ltd declared to strengthen strategic cooperation with Hangzhou Tigermed Consulting Co., Ltd. in biomedicines and jointly set up medical health industry M&A fund not lower than CNY 350 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300142:CH CNY28.06 CNY -0.26

300142 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300142.
View Industry Companies
 

Industry Analysis

300142

Industry Average

Valuation 300142 Industry Range
Price/Earnings 92.9x
Price/Sales 18.7x
Price/Book 4.6x
Price/Cash Flow 92.5x
TEV/Sales 14.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WALVAX BIOTECHNOLOGY CO-A, please visit www.walvax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.